Replies to post #210416 on Biotech Values

[DFRAI]

TRIL - why no comments regarding the rituximab combo with TTI621?

In the TTI-621/rituximab combination cohort, 3 of 6 patients who have had at least one interval PET/CT restaging obtained partial metabolic responses, as demonstrated by decreased tumor activity on PET/CT scans. These patients with CD20-positive, B-cell lymphoma received weekly IV infusions of TTI-621 and rituximab. Manageable infusion reactions occurred in most patients after the first infusion of TTI-621 and the combination therapy has been associated with acceptable outpatient tolerability. These responding patients remain on treatment and progression-free for 19+ (DLBCL), 18+ (transformed lymphoma), and 8+ weeks (follicular lymphoma) in continuing follow-up.

[biomaven0]

>>only one response out of 27 pts given monotherapy

But 1/1 with MRD AML, which the company said at Cowen was the indication they currently liked best.

Some more details here - this patient relapsed after a stem-cell transplant:

http://www.siliconinvestor.com/readmsg.aspx?msgid=31056707